Ergoset bromocriptine dopamine D2 agonist: Phase II data; NDA under review

ERGO said a Phase II trial of Ergoset in 22 patients with Type II diabetes showed a statistically significant improvement in insulin sensitivity versus placebo (p?0.01). Fasting plasma glucose was red...